ProteaPex Therapeutics is developing a novel method of Matrix Metalloprotease inhibition that is safe and highly specific when compared to classic MMP inhibitors. Our therapeutic is inexpensive, safe and can be applied directly to the diseased area.
The lead product in development for the human market, ECPF-1, has demonstrated efficacy as an osteoarthritis injectable therapeutic. ECPF-1 is a standout in the field, because it slows the progression of the disease without the side effects seen in skeletal tissues treated with MMP inhibitors currently in the market. LEARN ABOUT ECPF1